Utilizing Argatroban for Neuroendovascular Therapy in Heparin-Induced Thrombocytopenia: A Case Report and Technical Review
Argatroban is a viable and safe alternative to heparin in neuroendovascular procedures for patients with HIT. Intermittent bolus administration guided by ACT offers precise, situation-specific control and may be particularly appropriate for hemorrhagic cerebrovascular conditions such as dAVFs.
Authors
- Taichi Ishiguro (ORCID: https://orcid.org/0000-0002-6660-9316)
- Yuki Takano (ORCID: https://orcid.org/0000-0001-7301-1489)
- Yoshihiro Omura (ORCID: https://orcid.org/0000-0002-6935-5366)
- Makiko Sakaguchi
- Takashi Arai (ORCID: https://orcid.org/0000-0001-7182-3176)
- Kostadin Karagiozov (ORCID: https://orcid.org/0000-0001-6105-0480)
- Takakazu Kawamata (ORCID: https://orcid.org/0000-0002-6076-7065)
- Hiroki Eguchi (ORCID: https://orcid.org/0009-0009-2669-8965)
- Mana Suzuki
- Masahiko Nishitani
- Nobuhiko Momozaki (ORCID: https://orcid.org/0000-0002-5555-5228)
Institutions
- Tokyo Women's Medical University Hospital (JP)
- Tokyo Women's Medical University (JP)
- Tokyo Women's Medical University Yachiyo Medical Center
Publication Details
- Journal
- Journal of Neuroendovascular Therapy
- Published
- 2025-01-01
- DOI
- https://doi.org/10.5797/jnet.cr.2025-0090
- Primary Topic
- Heparin-Induced Thrombocytopenia and Thrombosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00